Jove
Visualize
联系我们

相关概念视频

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same journal

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026
Same journal

Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia.

Lancet (London, England)·2026
Same journal

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026
Same journal

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same journal

Temocillin as a carbapenem-sparing option for ESBL bloodstream infection.

Lancet (London, England)·2026
Same journal

WHO's operational role in emergencies: mandate and evolution.

Lancet (London, England)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 13, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

为了获得终身的乙型肝炎免疫力,是否需要进行增强免疫接种? 关于乙型肝炎免疫的欧洲共识小组

    Lancet (London, England)
    |February 22, 2000
    PubMed
    概括
    此摘要是机器生成的。

    乙型肝炎 (HB) 疫苗在免疫能力强的个体中提供至少15年的长期保护. 对于那些对初级疫苗接种过程有反应的人来说,通常不需要强剂量.

    更多相关视频

    HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
    07:18

    HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

    Published on: April 11, 2011

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    相关实验视频

    Last Updated: Jul 13, 2026

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
    08:52

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

    Published on: May 27, 2011

    HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
    07:18

    HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

    Published on: April 11, 2011

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    科学领域:

    • 免疫学 免疫学 免疫学
    • 疫苗学 疫苗学 疫苗学
    • 肝病学 肝病学是一种肝病学.

    背景情况:

    • 对乙型肝炎 (HB) 病毒感染的长期保护依赖于免疫记忆和历史抗体反应.
    • 对于HB疫苗接种的免疫记忆在免疫能力强的个体中持续至少15年.
    • 目前的数据不支持在已完成初级疫苗接种课程的免疫能力强的个体中需要强剂.

    研究的目的:

    • 评估在免疫能力强的人群中对乙型肝炎 (HB) 疫苗进行增强剂量的必要性.
    • 评估免疫的持续时间和增强剂在特定人群中的作用.

    主要方法:

    • 对初级乙型肝炎 (HB) 接种疫苗后长期免疫力的现有数据的审查.
    • 对接种疫苗的个体抗体持久性 (抗HBs) 和历史回应的分析.
    • 考虑免疫功能低下患者和不响应患者的增强剂策略.

    主要成果:

    • 具有初级响应的免疫能力强的人至少保持15年的免疫力,表现出持久的抗HBs和/或历史回应.
    • 目前没有数据支持在一次初级疫苗接种后,对免疫能力强的个体进行例行强剂.
    • 作为放心剂,或在免疫功能低下的个体中,当抗体标位低于10mIU/mL时,可以考虑使用强剂.

    结论:

    • 乙型肝炎 (HB) 疫苗在免疫能力强的个体中赋予持久免疫力,从而消除了常规增强剂的需要.
    • 免疫受损的个体需要定期监测和潜在的增强剂量.
    • 对所有接种疫苗的人来说,持续的长期监测是必不可少的,特别是那些没有反应的人.